Drug intelligence / Profile preview

venetoclax + pegcrisantaspase

Development stage: Unknown
Lead developer: University of Maryland, Baltimore
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of venetoclax, an oral BCL-2 inhibitor, and pegcrisantaspase, a pegylated form of crisantaspase that depletes plasma glutamine. This novel regimen works through synergistic mechanisms where venetoclax induces apoptosis by inhibiting BCL-2, while pegcrisantaspase depletes plasma glutamine, disrupts mRNA translation, and decreases expression of proteins like MCL-1. The combination has shown efficacy in relapsed/refractory acute myeloid leukemia (AML), including in patients who had previously progressed on venetoclax-based therapies.

Targets

BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on venetoclax + pegcrisantaspase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on venetoclax + pegcrisantaspase.

Explore the full profile